businesspress24.com - BioSyent Named to the PROFIT 500 Ranking of Canada''s Fastest-Growing Companies With a Fiv
 

BioSyent Named to the PROFIT 500 Ranking of Canada''s Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 815%

ID: 1458340

(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 09/15/16 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that Canadian Business and PROFIT today named BioSyent to the 28th annual PROFIT 500, the definitive ranking of Canada''s Fastest-Growing Companies. Published in the October issue of Canadian Business and at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their five-year revenue growth.

Based on a five-year revenue growth rate of 815% (2010-2015), BioSyent ranked 92nd on the 2016 PROFIT 500 list. This is the fourth consecutive year that BioSyent has been named to the PROFIT 500 list and the second consecutive year that it has been ranked in the top 100 fastest-growing companies.

"We are proud to be named to the PROFIT 500 list for the fourth consecutive year," commented Rene Goehrum, President and CEO of BioSyent. "We remain committed to building our brand portfolio with innovative products and continuing to execute on our strategy to deliver consistent, profitable growth."

"Companies become a part of the PROFIT 500 through innovative thinking, smart strategy and sheer grit," says James Cowan, Editor-in-chief of PROFIT and Canadian Business. "These firms demonstrate what Canadian entrepreneurs can achieve, both at home and across the globe."

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit .

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.





As of the date of this press release, the Company has 14,091,087 shares issued and outstanding.



Contacts:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  FutureLand Corp. (FUTL) With Major Funding Probing for Licensed Cannabis Grows, Dispensaries and Extraction Deals to Invest in
Premier Biomedical and Advanced Technologies Solutions Form Pain Management Joint Venture to Treat Generalized, Neuropathic and Localized Pain With Natural Cannabis-Based Products
Bereitgestellt von Benutzer: Marketwired
Datum: 15.09.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 1458340
Anzahl Zeichen: 2276

contact information:
Contact person:
Town:

TORONTO, ONTARIO


Phone:

Kategorie:

Alternative


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 230 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"BioSyent Named to the PROFIT 500 Ranking of Canada''s Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 815%
"
steht unter der journalistisch-redaktionellen Verantwortung von

BioSyent Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von BioSyent Inc.



 

Who is online

All members: 10 591
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 124


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.